Author(s): McComb S; Arbabi-Ghahroudi M; Hay KA; Keller BA; Faulkes S; Rutherford M; Nguyen T; Shepherd A; Wu C; Marcil A; Aubry A; Hussack G; Pinto DM; Ryan S; Raphael S; van Faassen H; Zafer A; Zhu Q; Maclean S; Chattopadhyay A; Gurnani K; Gilber ...

Chimeric antigen receptor (CAR) T cell therapies targeting B cell-restricted antigens CD19, CD20, or CD22 can produce potent clinical responses for some B cell malignancies, but relapse remains common. Camelid single-domain antibodies (sdAbs or nanobodies) are smaller, simpler, and easier to reco ...

Article GUID: 38596311

Author(s): Ahmadi F; Tran H; Letourneau N; Little SR; Fortin A; Moraitis AN; Shih SCC;

Monoclonal antibody (mAb) discovery plays a prominent role in diagnostic and therapeutic applications. Droplet microfluidics has become a standard technology for high-throughput screening of antibody-producing cells due to high droplet single-cell confinement frequency and rapid analysis and sorting of the cells of interest with their secreted mAbs. In th ...

Article GUID: 38441226

Author(s): Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ;

The Food and Drug Administration (FDA) has recently authorized the two messenger RNA (mRNA) vaccines BNT162b2 and mRNA-1273 for emergency use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the COVID-19 coronavirus disease. BNT162b2 and mRNA-1273 vaccines were developed by Pfizer-BioNTech and Moderna, respectively, in 2020 ...

Article GUID: 34021862